Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis

Expert Opinion on Investigational Drugs

Volumn 24, Issue 9, 2015, Pages 1229-1239

  Jaroszewicz, Jerzy ^a   Flisiak Jackiewicz, Marta ^a   Lebensztejn, Dariusz ^a   Flisiak, Robert ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

antifibrotic therapy; fibrosis; hepatitis C virus; inflammation; liver

Indexed keywords

ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; COLLAGEN; INTERFERON;

CHRONIC HEPATITIS C; CROSS LINKING; DISEASE ASSOCIATION; DRUG SAFETY; ELASTOGRAPHY; EXTRACELLULAR MATRIX; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LUNG FIBROSIS; META ANALYSIS (TOPIC); NON INVASIVE PROCEDURE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROLOGY; VIRAL CLEARANCE; ANIMAL; COMPLICATION; DISEASE COURSE; DRUG DESIGN; LIVER CIRRHOSIS; METABOLISM; PATHOPHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG DESIGN; EXTRACELLULAR MATRIX; HEPATITIS C; HUMANS; INTERFERONS; LIVER CIRRHOSIS;

EID: 84939787501     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1057568     Document Type: Review

References (97)

1. Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm-volume J Viral Hepatitis 2015;22(Suppl S1):26-45
2. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-Analysis and meta-regression. Hepatology 2008;48:418-31
3. Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide-filling the gaps. J Viral Hepatitis 2015;22(Suppl 1):1-5
4. Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV-myth or foreseeable future? Liver Int 2014;34:6-11
5. Weiskirchen R, Tacke F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr 2014;3:344-63
6. Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basisof antifibrotic therapies. Hepat Med 2011;3:69-80
7. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123:1887-901
8. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-9
9. Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005;39(Suppl 2):S158-61
10. Klein S, Van Beuge MM, Granzow M, et al. HSC-specific inhibition of Rhokinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012;57:1220-7
11. Ogawa S, Ochi T, Shimada H, et al. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res 2010;40:1128-41
12. Poelstra K, Schuppan D. Targeted therapy of liver fibrosis/cirrhosis and its complications. J Hepatol 2011;55:726-8
13. Lorenzer C, Dirin M, Winkler AM, et al. Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015; 203C:1-15
14. Canbay A, Feldstein A, Baskin-Bey E, et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004;308(3):1191-6
15. Masuoka HC, Guicciardi ME, Gores GJ. Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis 2009;13:467-75
16. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013;58:1028-41
17. Stockmann C, Kerdiles Y, Nomaksteinsky M, et al. Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci USA 2010;107:4329-34
18. Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 2011;300:G723-8
19. Hammerich L, Tacke F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol 2014;7:297-306
20. Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta 2013;1832:1061-9
21. Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis 2010;30:215-25
22. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32:593-604
23. Ramachandran P, Pellicoro A, Vernon MA, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci USA 2012;109:E3186-95
24. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009-17
25. EASL Recommendations on Treatment of Hepatitis C 2014. Available from: http://files.easl.eu/easl-recommendationson-treatment-of-hepatitis-C/index.html
26. AASLD-IDSA recommendations for testing, managing, and treating hepatitis C. 2014. Available from: http://www. hcvguidelines.org/full-report-view
27. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep 2014;16:1-7
28. Leroy V, Sturm N, Faure P, et al. Prospective evaluation of FibroTest, FibroMeter, and HepaScore for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol 2014;61:28-34
29. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26
30. Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, et al. A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B. Hepatology 2005;41:1434-5
31. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology 2007;46:32-6
32. Available from: http://www.hepatitisc.uw. edu/page/clinical-calculators
33. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:282-92
34. Gentile I, Coppola N, Pasquale G, et al. A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. Hepat Mon 2013;13:e8352
35. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005;41:1376-82
36. Gonzalez HC, Jafri SM, Gordon SC. Role of liver biopsy in the era of directacting antivirals. Curr Gastroenterol Rep 2013;15:307
37. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005;40:867-72
38. Poynard T, Morra R, Halfon P, et al. Meta-Analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7:40
39. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73
40. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-81
41. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferaseto-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46:912-21
42. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53:1013-21
43. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50
44. Bamber J, Cosgrove D, Dietrich CF, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall Med 2013;34:169-84
45. Potthoff A, Attia D, Pischke S, et al. Influence of different frequencies and insertion depths on the diagnostic accuracy of liver elastography by acoustic radiation force impulse imaging (ARFI). Eur J Radiol 2013;82:1207-12
46. Crespo G, Fernández-Varo G, Mariño Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol 2012;57:281-7
47. Ferraioli G, Tinelli C, Dal Bello B, et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012;56:2125-33
48. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-302
49. Calvaruso V, Crax A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int 2014;34:85-90
50. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75
51. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32
52. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
53. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13
54. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821-9
55. Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840-9
56. Haseltine EL, Penney MS, George S, et al. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis. J Viral Hepat 2015. [Epub ahead of print]
57. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93
58. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82
59. Welzel TM, Zeuzem S. Interferon-free strategies without a nucleoside/nucleotide analogue. Semin Liver Dis 2014;34:47-57
60. Feld JJ. Interferon-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis 2014;34(1):37-46
61. Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12:763-73
62. Shiffman ML, Kowdley KV, Poordad F, et al. Trends in liver fibrosis testing, hepatic synthetic function, and platelet counts at baseline and 12 weeks after treatment with ABT-450/r/ombitasvir and dasabuvir with ribavirin in HCV genotype 1-infected patients with cirrhosis. Hepatology 2014;60(Suppl 1):1962
63. Wedemeyer H, Berg T, Flamm SL, et al. Improvement in liver function and noninvasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/r, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis. J Hepatol 2015;62(Suppl 2):S637
64. Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT Part A). J Hepatol 2015;62(Suppl 2):S193
65. Afdhal N, Everson GT, Calleja JL, et al. Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol 2015;62(Suppl 2):S269
66. Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-Analysis. Liver Int 2015;35:30-6
67. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93
68. Torok NJ, Dranoff JA, Schuppan D, et al. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015; Epub ahead of print
69. Hsu SJ, Lee FY, Wang SS, et al. Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats. Hepatology 2014. [Epub ahead of print]
70. Goh GB, Chow WC, Wang R, et al. Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology 2014;60:661-9
71. Batista MN, Carneiro BM, Braga AC, Rahal P. Caffeine inhibits hepatitis C virus replication in vitro. Arch Virol 2015;160:399-407
72. Freedman ND, Curto TM, Morishima C, et al. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther 2011;33:127-37
73. Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003;38:859-68
74. Golden-Mason L, Rosen HR. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev 2013;255:68-81
75. Krämer B, Korner C, Kebschull M, et al. Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 2012;56:1201-13
76. Langhans B, Alwan AW, Krämer B, et al. Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type. J Hepatol 2015;62:398-404
77. Mitra A, Satelli A, Yan J, et al. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology 2014;60:2027-39
78. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014;147:765-83
79. Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-Alcoholic steatohepatitis. Liver Int 2015;35:953-66
80. Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013;4:2823
81. Ray K. Liver: Key role for av integrins in myofibroblasts in liver fibrosis. Nat Rev Gastroenterol Hepatol 2014;11:4
82. Henderson NC, Arnold TD, Katamura Y, et al. Targeting of av integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013;19:1617-24
83. Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol 2015. [Epub ahead of print]
84. King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92
85. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97
86. Armendáriz-Borunda J, Islas-Carbajal MC, Meza-Garcá E, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006;55:1663-5
87. Flores-Contreras L, Sandoval-Rodríguez AS, Mena-Enriquez MG, et al. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol 2014;14:131
88. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:742-55
89. Oakley F, Teoh V, Ching-A-Sue G, et al. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 2009;136:2334-44
90. Colmenero J, Bataller R, Sancho-Bru P, et al. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 2009;297:G726-34
91. Cales P, Bacq Y, Vine JP, et al. rbesartan for severe fibrosis in chronic hepatitis C: a double-blind randomized trial (ANRS HC19 Fibrosar). Hepatology 2014;60(Suppl 1):423A
92. Aoyama T, Paik YH, Watanabe S, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 2012;56:2316-27
93. Jiang JX, Chen X, Serizawa N, et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 2012;53:289-96
94. Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008;26:431-42
95. Ishiwatari H, Sato Y, Murase K, et al. Treatment of pancreatic fibrosis with siRNA against a collagen-specific chaperone in vitamin A-coupled liposomes. Gut 2013;62:1328-39
96. Moon HJ, Finney J, Ronnebaum T, Mure M. Human lysyl oxidase-like 2. Bioorg Chem 2014;57:231-41
97. Ikenaga N, Yoshida S, Liu SB, et al. Targeting lysyl oxidase like 2 (LOXL2) inhibits collagen cross-linking and accelerates reversal of pre-established liver fibrosis. J Hepatol 2013;58(Suppl 1):243-4